Unlocking the Therapeutic Potential: Intravenous Glutamine Therapy

Speciality: Emergency Medicine


Speaker:

Dr. Paul Wischmeyer | Professor in University of Colorado school of medicine

Description:

A warm welcome to all the medical professionals in this interesting session on the potential benefits of intravenous glutamine therapy.

Intravenous (IV) glutamine therapy has garnered attention for its potential therapeutic benefits in various clinical settings. Glutamine, an amino acid, plays a crucial role in numerous physiological processes, including protein synthesis, immune function, and cellular metabolism. 

IV administration of glutamine bypasses the digestive system, allowing for rapid absorption and delivery of this essential nutrient directly into the bloodstream. This method is particularly beneficial for patients with conditions such as critical illness, sepsis, and intestinal failure, where oral intake may be compromised or insufficient. IV glutamine supplementation aims to replenish depleted glutamine stores, support immune function, and promote tissue repair and recovery in critically ill patients.

The use of IV glutamine therapy extends beyond critical care settings, with emerging evidence suggesting potential benefits in other clinical scenarios. For example, IV glutamine has shown promise in reducing chemotherapy-induced mucositis and improving outcomes in patients undergoing bone marrow transplantation. 

Therefore, get an overall knowledge on the understanding of the potential benefits of intravenous glutamine therapy. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot